Web Exclusives | February 19, 2019
On February 12, 2019, the US Food and Drug Administration (FDA) granted approval for daratumumab (Darzalex; Janssen), a CD38-directed antibody, to be given in a split-dosing regimen to patients with multiple myeloma (MM). Darzalex is the first and only CD38-directed antibody to receive regulatory approval for the treatment of patients with MM and is the first to be approved for the split-dosing regimen. This new regimen gives patients and healthcare providers the option to split the first dose of Darzalex over the course of 2 consecutive days, which has the benefit of shortening the duration of the first infusion.
Web Exclusives | October 2, 2018
The Academy of Oncology Nurse & Patient Navigators (AONN+) is pleased to announce Dr Jill Biden as the Keynote Speaker for the Ninth Annual Navigation & Survivorship Conference.
Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation
Web Exclusives | May 15, 2018
These results make quizartinib the first FLT3 inhibitor to demonstrate such improvement over chemotherapy in this patient population.
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
Web Exclusives | April 7, 2018
NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression.
With Emerging Oncology Therapies and Rising Patient Responsibilities, Financial Navigation Will Have a Greater Role in Cancer Care
Web Exclusives | January 18, 2018
Emerging pharmacologic therapies used for the treatment of oncology are being developed and approved at an accelerated rate.
Web Exclusives | April 17, 2017
AONN+ Navigation Metrics can be incorporated into partnerships between oncology patient navigators and physician practices.
Results 1 - 11 of 11